Exacerbation of branch retinal vein occlusion post SARS-CoV2 vaccination: Case reports |
| |
| Authors: | Hayato Tanaka Daisuke Nagasato Shunsuke Nakakura Hirotaka Tanabe Toshihiko Nagasawa Hiroyuki Wakuda Yoko Imada Yoshinori Mitamura Hitoshi Tabuchi |
| |
| Affiliation: | aDepartment of Ophthalmology, Tsukazaki Hospital, Himeji, Hyogo, Japan;bDepartment of Technology and Design Thinking for Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Hiroshima, Japan;cDepartment of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Tokushima, Japan;dImada Eye Clinic, Kasai, Hyogo, Japan. |
| |
| Abstract: | Rationale:In this paper, we report on 2 patients who developed branch retinal vein occlusion (BRVO) exacerbation 1 day after administration of the BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine.Patient concerns:Case 1: A 71 year-old female developed vision loss in her left eye 1 day after receiving a second dose of the SARS-CoV-2 mRNA vaccine. This patient was diagnosed with temporal inferior BRVO and secondary macular edema (ME) in her left eye. ME resolved after 3 doses of intravitreal aflibercept (IVA). After treatment, no recurrence of ME was observed.Case 2: A 72 year-old man developed vision loss in his right eye 1 day after receiving the first dose of the SARS-CoV-2 mRNA vaccine. This patient was diagnosed with temporal superior BRVO in the right eye without ME. The patient was followed up and did not undergo any additional treatment.Diagnoses:Case1: Temporal superior BRVO and secondary ME were observed in the left eye. Her best-corrected visual acuity (BCVA) was 20/30.Case2: Temporal superior BRVO recurrence and secondary ME were observed in the right eye. BCVA was 20/25.Interventions:Case1: Additional dose of IVA was administered. Case2: Two times of Intravitreal ranibizumab was administered twice.Outcomes:Case1: Subsequently, ME resolved BCVA was 20/20. Case2: Subsequently, ME resolved BCVA was 20/25.Lessons:Both cases showed a possible association between SARS-CoV-2 vaccination and the exacerbation of BRVO. |
| |
| Keywords: | adverse reaction branch retinal vein occlusion case report COVID-19 vaccination |
|
|
